info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)
Certified Global Research Member
Isomar 1 Iso 1
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Acoustic Neuroma Market Size, Growth Research Report By Type (Unilateral, Bilateral) By Diagnosis (Audiometry, Electronystagmography, MRI) By Treatment (Monitoring, Surgery, Radiaotherapy, Supportive Therapy) By Drug Class, By End User - Competitor Industry Analysis and Trends Forecast Till 2032


ID: MRFR/MED/3671-HCR | 85 Pages | Author: Rahul Gotadki| September 2025

Global Acoustic Neuroma Market Overview

Acoustic Neuroma Market Size was valued at USD 1.9 Billion in 2023. The Global Acoustic Neuroma industry is projected to grow from USD 2.7 Billion in 2024 to USD 4.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.43% during the forecast period (2024 - 2032). 

An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.

Acoustic Neuroma Market

Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.

Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the acoustic neuroma market.

Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore,  these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).

The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.

Intended Audience

    • Acoustic Neuroma Drug Suppliers
    • Acoustic Neuroma Drug Manufacturers
    • Research And Development (R&D) Companies
    • Medical Research Laboratories
    • Academic Medical Institutes and Universities

Acoustic Neuroma Market Segmentation

The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.

Acoustic Neuroma Type Insights

On the basis of type, the Acoustic Neuroma Market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.

Acoustic Neuroma Diagnosis Insights

On the basis of diagnosis, the Acoustic Neuroma Market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.

Acoustic Neuroma Drug Class Insights

On the basis of drug class, the Acoustic Neuroma Market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.

Acoustic Neuroma Treatment Insights

On the basis of treatment, the Acoustic Neuroma Markett is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is subsegmented radiosurgery, craniotomy, and microsurgery removal.

Acoustic Neuroma End-User Insights

On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.

Acoustic Neuroma Regional Insights

The acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America is projected to hold the largest share of the acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).

The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.

Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.

Acoustic Neuroma Market Key Players

Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.

Some of key the players in the acoustic neuroma market are: 

    • GE Healthcare (U.S.)
    • Philips Healthcare (U.S.)
    • Shimadzu Corporation (Japan)
    • Toshiba Medical Systems Corporation (Japan)
    • F. Hoffmann-La Roche Ag
    • Merck & Co., Inc.
    • Novartis AG

Acoustic Neuroma Market Industry Developments

  • Q2 2024: Elekta receives FDA clearance for Leksell Gamma Knife Lightning for radiosurgery Elekta announced FDA clearance for its Leksell Gamma Knife Lightning software, which enhances precision in radiosurgery for conditions including acoustic neuroma. The approval enables expanded use of the system in U.S. neurosurgical centers.
  • Q1 2024: Pfizer appoints Dr. Susan Hockfield to Board of Directors Pfizer announced the appointment of Dr. Susan Hockfield, a neuroscientist, to its Board of Directors, strengthening its expertise in neurological disorders including acoustic neuroma.
  • Q2 2024: Roche launches new diagnostic imaging platform for cranial nerve tumors Roche introduced a new imaging platform designed to improve early detection of cranial nerve tumors such as acoustic neuroma, aiming to support more accurate diagnosis and treatment planning.
  • Q2 2024: Natus Medical opens new neurodiagnostic facility in Boston Natus Medical Incorporated announced the opening of a new neurodiagnostic center in Boston, expanding access to advanced diagnostic services for patients with acoustic neuroma and other neurological conditions.
  • Q3 2024: Elekta partners with Mayo Clinic for radiosurgery research in acoustic neuroma Elekta entered a research partnership with Mayo Clinic to advance radiosurgery techniques for acoustic neuroma, focusing on improving patient outcomes and treatment precision.
  • Q2 2025: Amgen announces acquisition of neuro-oncology startup focused on acoustic neuroma therapies Amgen completed the acquisition of a neuro-oncology startup developing targeted therapies for acoustic neuroma, expanding its portfolio in neurological disease treatment.
  • Q1 2025: Elekta raises $200M in public offering to expand radiosurgery business Elekta raised $200 million in a public offering to support the expansion of its radiosurgery business, including technologies for treating acoustic neuroma.
  • Q2 2025: Pfizer announces partnership with University of California for acoustic neuroma research Pfizer entered a partnership with the University of California to conduct research on novel therapies for acoustic neuroma, aiming to accelerate drug development in the field.
  • Q2 2024: Roche receives CE mark for new MRI contrast agent for cranial nerve tumor imaging Roche received CE mark approval for its new MRI contrast agent, designed to improve imaging of cranial nerve tumors such as acoustic neuroma in European markets.
  • Q3 2024: Natus Medical secures contract with NHS for neurodiagnostic equipment Natus Medical secured a contract with the UK National Health Service to supply neurodiagnostic equipment for the detection and monitoring of acoustic neuroma.
  • Q1 2025: Startup NeuroSurg raises $50M Series B to develop minimally invasive acoustic neuroma treatment NeuroSurg, a medical technology startup, raised $50 million in Series B funding to advance development of minimally invasive treatments for acoustic neuroma.
  • Q2 2025: Elekta files patent for new radiosurgery device targeting acoustic neuroma Elekta filed a patent for a new radiosurgery device specifically designed for the treatment of acoustic neuroma, aiming to improve precision and patient safety.
Attribute/Metric Details
Market Size 2023 1.9 (USD Billion)
Market Size 2024 2.7 (USD Billion)
Market Size 2032 4.3 (USD Billion)
Compound Annual Growth Rate (CAGR) 9.43 % (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others
  Key Market Opportunities The key players which grants various opportunities for the acoustic neuroma market.
  Key Market Drivers  Increasing cases of acoustic neurom


Frequently Asked Questions (FAQ):

acoustic neuroma market is expected to expand exponentially at 9.34% CAGR from 2024 to 2032.

acoustic neuroma market is driven by the increasing cases of acoustic neurom

Diagnosis of acoustic neuroma by gadolinium enhanced magnetic resonance imaging (MRI) is expected to be beneficial to the global acoustic neuroma market in the coming years.

The probability of severe headaches after surgery can impede by the global acoustic neuroma market growth.

North America can dominate the global acoustic neuroma market till 2025.

Pfizer Inc., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ag, Toshiba Medical Systems Corporation, GE Healthcare, Philips Healthcare, Shimadzu Corporation, and Siemens Healthcare are notable players currently working in the global acoustic neuroma market.

Comments

Leading companies partner with us for data-driven Insights.

clients

Kindly complete the form below to receive a free sample of this Report

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
report-img